Xtant Medical (XTNT) Q2 2024 earnings summary

Executive summary

• Revenue grew 48% year-over-year to $29.9 million in Q2 2024, driven by acquisitions, especially Surgalign, and expanded product offerings.

• Net loss widened to $3.9 million from $2.2 million year-over-year, reflecting higher operating expenses from growth initiatives and integration costs.

• Achieved fifth consecutive quarter of positive Adjusted EBITDA at $0.5 million.

• Integration of 2023 acquisitions progressing well, supporting strategic replacement of aging product lines and market expansion.

• Launched new amniotic membrane allograft products and signed 15 new distributors, expanding the sales network.

Financial highlights

• Q2 2024 revenue: $29.9 million, up from $20.2 million in Q2 2023 (48% increase).

• Gross margin: 62.1% in Q2 2024, up from 61.6% in Q2 2023, due to scale and production efficiency.

• Operating expenses: $21.5 million (71.9% of revenue), up from $13.9 million (68.5%) in Q2 2023, mainly due to higher compensation and integration costs.

• Net loss: $3.9 million (3 cents/share) in Q2 2024, compared to $2.2 million (2 cents/share) in Q2 2023.

• Cash and cash equivalents at June 30, 2024: $5.4 million.

Outlook and guidance

• Full-year 2024 revenue guidance reaffirmed at $116–$120 million, representing 27–31% annual growth.

• Expects sequential revenue growth in Q3 and Q4, with Q4 typically stronger seasonally.

• Anticipates double-digit organic growth in H2 2024 as new products and supply chain improvements take effect.

• Gross margins expected to remain steady in Q3 and Q4, with more significant improvement in Q1 2025 as in-house stem cell production ramps up.

• Targeting positive operating cash flow in Q4 2024, with sustainability expected after Q1 2025.